Table 2 Relationship of cuproptosis-related genes and cancer

FDX1

KIRC

Down

Increased expression of FDX1 was associated with a more favorable OS in patients with KIRC. A lower expression of FDX1 may heighten the responsiveness to immunotherapies in patients

[127]

HCC

Down

Higher FDX1 expression demonstrated prolonged survival in HCC. High FDX1 levels were correlated with a decrease in PD-1 expression, as well as an enhancement in natural killer cells, macrophages, and B cells within tumor tissues

[128, 129]

Glioma

Up

FDX1 acted as a risk factor for OS in glioma

[130]

Thyroid carcinoma

Down

Higher FDX1 expression was correlated with the OS in patients with thyroid carcinoma

[131]

ACC

Down

Higher FDX1 expression was associated with longer survival in patients with ACC

[132]

CRC

Down

Low FDX1 expression was associated with poorer OS in patients with CRC

[133]

LIAS

Glioma

Up

High LIAS expression was associated with poorer OS in patients with glioma

[134]

Lung cancer

Up

High LIAS expression was associated with poorer OS in patients with lung cancer

[135]

KIRC

Down

High LIAS expression was linked with good OS and DSF in patients with KIRC

[135]

READ

Down

High LIAS expression displayed good OS in patients with READ

[135]

Ovarian cancer

Down

High LIAS expression displayed good OS and PFS in patients with ovarian cancer

[135]

Breast cancer

Down

High LIAS expression was linked with good OS in patients with breast cancer

[135]

LIPT1

Glioma

Up

LIPT1 was a risk factor for OS in patients with glioma

[130]

LIHC

Up

Low LIPT1 expression was associated with significantly longer OS in patients with LIHC

[136]

HCC

Up

High LIPT1 expression was associated with more malignant pathological features and poor prognosis in patients with HCC

[137]

NSCLC

Down

High LIPT1 expression was associated with a favorable prognosis for patients with NSCLC

[138]

PAAD

Down

LIPT1 acted as a protective factor for OS in patients with PAAD. Silencing LIPT1 promotes the proliferation, migration, and invasion of PANC-1 and SW1990 cells

[139]

DLAT

Glioma

Up

High DLAT expression was associated with poorer survival in patients with glioma

[134]

ESCA

Up

DLAT acted as a risk factor for OS in patients with ESCA

[140]

BRCA

Down

DLAT acted as a risk factor for OS in patients with BRCA

[140]

COAD

Down

DLAT served as a protective factor for OS in patients with COAD

[140]

READ

Down

DLAT served as a protective factor for OS in patients with READ

[140]

KIPAN

Down

DLAT served as a protective factor for OS in patients with KIPAN

[140]

KIRP

Down

DLAT served as a protective factor for OS in patients with KIRP

[140]

LIHC

Up

High expression levels of DLAT were linked with poor OS in patients with LIHC. Elevated levels of DLAT were identified in patients exhibiting resistance to 5-fluorouracil and lenvatinib. Higher levels of DLAT expression were correlated with elevated PD-L1 levels

[140,141,142]

PAAD

Up

Elevated DLAT expression in PAAD was correlated with increased resistance to a range of chemotherapeutics, including gemcitabine, irinotecan, 5-fluorouracil, and oxaliplatin

[143]

KIRC

Down

High expression levels of DLAT were linked with good OS in patients with KIRC

[140, 142, 144]

LUAD

Up

High expression levels of DLAT were associated with worse outcomes in patients with LUAD

[145]

GLS

PCA

Up

High expression of GLS was significantly associated with Gleason score and tumor stage

[146]

CDNK2A

Pan-cancer

CDKN2A mutations that prevent its binding to CDKs can lead to uncontrolled growth in various tumors, including NSCLC, PAAD, HNSCC, breast, and ovarian cancers. Epigenetic reduction of CDKN2A level changed the expression of cancer-related oncogenes or tumor suppressor genes and promoted tumorigenesis

[147]

MTF1

Gastric cancer

Down

High MTF1 expression was associated with longer OS in patients with gastric cancer

[148]

LIHC

Up

High MTF1 expression was related to poor prognosis in patients with LIHC

[149, 150]

LGG

Up

High MTF1 expression was related to poor prognosis in patients with LGG

[149]

KIRC

Down

High MTF1 expression was associated with a good prognosis in patients with KIRC

[149]

Lung cancer

Down

High MTF1 expression was associated with good prognosis in patients with lung cancer

[149]

Ovarian cancer

Down

High MTF1 expression was associated with good prognosis in patients with ovarian cancer

[149]

Breast cancer

Down

High MTF1 expression was associated with good prognosis in patients with breast cancer

[149]

SLC31A1

Glioma

Up

SLC31A1 was a risk factor for OS in patients with glioma

[130]

Breast cancer

Up

High SLC31A1 expression was correlated with a poorer prognosis in patients with breast cancer

[151,152,153]

BRCA

Up

Higher SLC31A1 expression was associated with worse OS in patients with BRCA

[154]

STAD

Up

Lower SLC31A1 expression was associated with worse OS and DSF in patients with STAD

[154]

KIRC

Down

Lower SLC31A1 expression was associated with worse OS and DSF in patients with KIRC

[154]

LGG

Up

Low SLC31A1 expression was associated with good OS in patients with LGG

[155]

Bladder cancer

Up

Higher SLC31A1 expression was associated with worse OS in patients with bladder cancer

[156]

PDHA1

Glioma

Down

PDHA1 was a favorable factor for prognosis in patients with glioma

[130]

HCC

Up

High PDHA1 expression was associated with a poor survival rate in patients with HCC

[157]

OSCC

Down

Low PDHA1 expression was correlated with good survival in patients with OSCC

[158]

ATP7A

Glioma

Up

ATP7A were risk factors for OS in patients with glioma

[130]

HCC

Up

High ATP7A expression was correlated with a poorer prognosis in patients with HCC. Low expression of ATP7A increased HCC cell copper accumulation and suppressed tumor cell growth

[159]

OSCC

Down

Low ATP7A expression was correlated with good survival in patients with OSCC

[158]

ATP7B

Glioma

Up

ATP7B were favorable factors for OS in patients with glioma

[130]